PGE2 Contributes to In vitro MSC-Mediated Inhibition of Non-Specific and Antigen-Specific T Cell Proliferation in MS Patients

Scandinavian Journal of Immunology

Volumn 78, Issue 5, 2013, Pages 455-462

  Zafranskaya, M ^a   Nizheharodava, D ^a   Yurkevich, M ^a   Ivanchik, G ^a   Demidchik, Y ^a   Kozhukh, H ^b   Fedulov, A ^c  

^a BELARUSIAN MEDICAL ACADEMY OF POSTGRADUATE EDUCATION   (Belarus)

^b Belarusian Research and Production Center for Hematology and Transfusiology   (Belarus)

^c BELARUSIAN STATE MEDICAL UNIVERSITY   (Belarus)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGENIC AGENT; MYELIN; PROSTAGLANDIN E2; PHYTOHEMAGGLUTININ;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN SPECIFICITY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTIPLE SCLEROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; T LYMPHOCYTE; CELL COMMUNICATION; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMA CELL; METABOLISM; YOUNG ADULT;

ADULT; CELL COMMUNICATION; CELL PROLIFERATION; CELLS, CULTURED; DINOPROSTONE; FEMALE; HUMANS; IMMUNOSUPPRESSION; LYMPHOCYTE ACTIVATION; MALE; MESENCHYMAL STROMAL CELLS; MITOGENS; MULTIPLE SCLEROSIS; PHYTOHEMAGGLUTININS; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84886745438     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12102     Document Type: Article

References (31)

1. Buzzard KA, Broadley SA, Butzkueven H. What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis? Int J Mol Sci 2012;13:12665-709.
2. Page EK, Dar WA, Knechtle S. Tolerogenic therapies in transplantation. Front Immunol 2012;3:198.
3. Salem HK, Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 2010;28:585-96.
4. Ghannam S, Bouffi C, Djouad F, Jorgensen C, Noël D. Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther 2010;1:2.
5. English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4 + CD25(High) forkhead box P3 + regulatory T cells. Clin Exp Immunol 2009;156:149-60.
6. Duffy MM, Ritter T, Ceredig R, Griffin M. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther 2011;2:34.
7. Sajic M, Hunt DP, Lee W et al. Mesenchymal stem cells lack efficacy in the treatment of experimental autoimmune neuritis despite in vitro inhibition of T-cell proliferation. PLoS ONE 2012;7:e30708.
8. Al Jumah MA, Abumaree MH. The immunomodulatory and neuroprotective effects of mesenchymal stem cells (MSCs) in experimental autoimmune encephalomyelitis (EAE): a model of multiple sclerosis (MS). Int J Mol Sci 2012;13:9298-331.
9. Bai L, Lennon DP, Eaton V et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 2009;57:1192-203.
10. Gerdoni E, Gallo B, Casazza S et al. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol 2007;61:219-27.
11. Kassis I, Grigoriadis N, Gowda-Kurkalli B et al. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol 2008;65:753-61.
12. Morando S, Vigo T, Esposito M et al. The therapeutic effect of mesenchymal stem cell transplantation in experimental autoimmune encephalomyelitis is mediated by peripheral and central mechanisms. Stem Cell Res Ther 2012;3:3.
13. Darlington P, Boivin M-N, Bar-Or A. Harnessing the therapeutic potential of mesenchymal stem cells in multiple sclerosis. Expert Rev Neurother 2011;11:1295-303.
14. Chen P-M, Yen M-L, Liu K-Ob{cyrillic}, Sytwu H-K, Yen B-L. Immunomodulatory properties of human adult and fetal multipotent mesenchymal stem cells. J Biomed Sci 2011;18:49.
15. Rubtsov YP, Suzdaltseva YG, Goryunov KV, Kalinina NI, Sysoeva VY, Tkachuk VA. Regulation of immunity via multipotent mesenchymal stromal cells. Acta Naturae 2012;4:23-31.
16. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815-22.
17. Newman RE, Yoo D, LeRoux MA, Danilkovitch-Miagkova A. Treatment of inflammatory diseases with mesenchymal stem cells. Inflamm Allergy Drug Targets 2009;8:110-23.
18. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-7.
19. Zafranskaya MM, Nizheharodava DB, Yurkevich MY et al. In vitro assessment of mesenchymal stem cells immunosuppressive potential in multiple sclerosis patients. Immunol Lett 2013;149:9-18.
20. Bifari F, Pacelli L, Krampera M. Immunological properties of embryonic and adult stem cells. World J Stem Cells 2010;2:50-60.
21. Di Nicola M, Carlo-Stella C, Magni M et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002;99:3838-43.
22. Krampera M, Glennie S, Dyson J et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003;101:3722-9.
23. + T-cell reactivity in multiple sclerosis. Immunology 2007;121:29-39.
24. Kang JW, Kang K-S, Koo HC, Park JR, Choi EW, Park YH. Soluble factors-mediated immunomodulatory effects of canine adipose tissue-derived mesenchymal stem cells. Stem Cells Dev 2008;17:681-94.
25. Solchaga LA, Zale EA. Prostaglandin E2: a putative potency indicator of the immunosuppressive activity of human mesenchymal stem cells. Am J Stem Cells 2012;1:138-45.
26. Yagi H, Soto-Gutierrez A, Parekkadan B et al. Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant 2010;19:667-79.
27. Lord AM, North TE, Zon LI. Prostaglandin E2. Cell Cycle 2007;6:3054-7.
28. Yanez R, Oviedo A, Aldea M, Bueren JA, Lamana ML. Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissue-derived mesenchymal stromal cells. Exp Cell Res 2010;316:3109-23.
29. Tilley SL, Coffman TM, Koller BH. Mixed message: modulation of inflammation and immune responses by prostaglandins and thromboxane. J Clin Invest 2001;108:15-9.
30. Ren G, Su J, Zhang L et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 2009;27:1954-62.
31. Krampera M, Cosmi L, Angeli R et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006;24:386-98.